Cover Image
市場調查報告書

全球幹細胞治療市場未來展望

Global Stem Cell Therapy Market Future Outlook

出版商 KuicK Research 商品編碼 334104
出版日期 內容資訊 英文 300 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球幹細胞治療市場未來展望 Global Stem Cell Therapy Market Future Outlook
出版日期: 2015年07月06日 內容資訊: 英文 300 Pages
簡介

本報告提供全球幹細胞治療市場相關調查、全球市場分析、幹細胞研究趨勢、幹細胞市場動態、全球市場動態、關於各企業、罹患率、階段的幹細胞治療藥的臨床實驗平台、臨床、前臨床開發平台上的幹細胞治療藥、市售的幹細胞治療藥,及主要企業簡介等等考察。

第1章 幹細胞的簡介

第2章 幹細胞的分類

  • 分化能力的基礎
  • 複製起點的基礎
  • 來源的基礎

第3章 幹細胞移植的各種類

  • 自體幹細胞移植
  • 同種異體幹細胞移植
  • 同一系統幹細胞移植

第4章 幹細胞治療的機制

第5章 幹細胞研究趨勢

  • 心血管疾病之幹細胞治療藥
  • 癌症治療幹之細胞治療藥
  • 中樞神經系統疾病之幹細胞治療藥
  • 眼科疾病之幹細胞治療藥
  • 代謝疾病之幹細胞治療藥
  • 腸胃 (消化管) 疾病之幹細胞治療藥

第6章 全球幹細胞市場分析

  • 市場現狀
  • 全球幹細胞治療藥開發平台概要

第7章 全球幹細胞市場動態

  • 可喜的要素
  • 商業化的問題

第8章 幹細胞市場未來展望

第9章 全球幹細胞治療藥臨床開發平台、企業,適應症及各階段

  • 研究中
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第三階段
  • 已透過核准

第10章 市售幹細胞治療藥的考察

  • 脂肪幹細胞治療藥 (Adipocell)
  • 血管來源的細胞前驅體治療藥(VesCell)

第11章 在臨床實驗平台中中止的幹細胞治療藥

第12章 競爭情形

企業清單

目錄

Stem cells are specialized cells that can differentiate into other cells without losing their identity. They have been found to be present in animals as well as humans and most of the work has been done on mice. Investigators have found that stem cells are part of repair system and helps in maintaining the normal bodily functions. They divide to give rise to two cells out of which one remains the same while other differentiates into the required cell type. They can replenish throughout the life-time and they could repair damaged organs in order to prevent further damage. They are also influenced by external cues due to which they could be converted into different cell type. It is expected that investigators would be able to make new discoveries that would allow them to assign new properties to stem cells. More research is required in this segment to fully understand the properties of stem cells.

Investigators are trying to decipher stem cells biochemical and biophysical properties so that they could develop them as a therapeutic commodity. Their ability to convert into different cell types could be used for developing regenerative medicines. Organ regeneration at laboratory levels have been achieved but it will take some time for developing fully functional transplantable organ. Investigators have found they could be used for various oncological applications. Modified stem cells could be used for curing cancer and some success has been achieved in past years. Their utility in cardiovascular diseases has been noted as they have ability to regenerate damaged cardiac muscles. In neural disorders like Alzheimer's disease and Parkinson's disease their role is being studied as presently available therapeutics have modest efficacy with short-lived effects.

Innovations in pharmaceutical industry seem to be the main driving force for the development of stem cell therapies. Investigators have been able to identify different stem cell sources which offers them large base for developing new therapies. Their customizability and appropriate usage is expected to help them to discover new pharmacological properties that may have high commercialization potential. As a result, large numbers of stem cell therapies are entering in clinical trials across the globe. They are at different stages of development and likely to be introduced in global market in coming years. This will help the stem cell therapy developers to generate significant revenues in coming years. However, this scenario may take few years to materialize but some stem cell therapies have already entered in market which are in clinical practice for past years.

As per recent research report "Global Stem Cell Therapy Market Future Outlook " published by KuicK Research, advancement in stem cell research seems to be increasing continuously across the globe which is apparent from the number of increasing clinical trials. Stem cell therapies for numerous indications are at different stages of clinical trials and they would be introduced in market in coming years. Increased findings and quest for better therapeutics could be considered as main reason behind growth of this segment. Improved technology and development of innovative modalities are further expected to propel the development of stem cell therapies. Only few stem cell therapies have received approval and most of them are small part of forth coming medical revolution. Stem cell therapy developers would be able to generate significant revenues in coming years. In this way, future prospects of stem cell therapies look optimistic and it is expected that more stem cell therapies would be commercialized in coming years.

"Global Stem Cell Therapy Market Future Outlook" Report Highlight:

  • Global Stem Cell Market Analysis
  • Trends in Stem Cell Research
  • Global Stem Cell Market Dynamics: Favorable Factors & Commercialization Challenges
  • Global Stem Cell Therapies Clinical Pipeline by Company, Indication & Phase
  • Global Stem Cell Therapies in Clinical Pipeline: 114 Therapies
  • Majority Stem Cell Therapies in Preclinical Phase: 38 Therapies
  • Marketed Stem Cell Therapies Clinical Insight by Brand Name, Company & Indication
  • Marketed Stem Cell Therapies Clinical: 2 Therapies (Adipocell® & VesCell™)

Table of Contents

1. Introduction to Stem Cells

2. Classification of Stem Cells

  • 2.1 Basis of Ability to Differentiate
  • 2.2 Basis of Origin
  • 2.3 Basis of their Source

3. Different Type of Stem Cell Transplants

  • 3.1 Autologous Stem Cell Transplants
  • 3.2 Allogeneic Stem Cell Transplants
  • 3.3 Syngeneic Stem Cell Transplants

4. Mechanism of Stem Cell Therapy

5. Trends in Stem Cell Research

  • 5.1 Stem Cell Therapy for Cardiovascular Diseases
  • 5.2 Stem Cell Therapy for Cancer Treatment
  • 5.3 Stem Cell Therapy for Central Nervous System Disorders
  • 5.4 Stem Cell Therapy for Ophthalmic Disorders
  • 5.5 Stem Cell Therapy for Metabolic Disorders
  • 5.6 Stem Cell Therapy for Gastrointestinal Diseases

6. Global Stem Cell Market Analysis

  • 6.1 Current Market Scenario
  • 6.2 Global Stem Cell Therapies Pipeline Overview

7. Global Stem Cell Market Dynamics

  • 7.1 Favorable Factors
  • 7.2 Commercialization Challenges

8. Stem Cell Market Future Prospects

9. Global Stem Cell Therapies Clinical Pipeline by Company, Indication & Phase

  • 9.1 Research
  • 9.2 Preclinical
  • 9.3 Clinical
  • 9.4 Phase-I
  • 9.5 Phase-I/II
  • 9.6 Phase-II
  • 9.7 Phase-III
  • 9.8 Registered

10. Marketed Stem Cell Therapies Clinical Insight by Brand Name, Company & Indication

  • 10.1 Adipose Stem Cell Therapy (Adipocell®)
  • 10.2 Angiogenic Cell Precursor Therapy (VesCell™)

11. Discontinued & Suspended Stem Cell Therapies in Clinical Pipeline

  • 11.1 No Development Reported
  • 11.2 Discontinued
  • 11.3 Suspended

12. Competitive Landscape

  • 12.1 Aldagen
  • 12.2 AlloCure
  • 12.3 Anterogen
  • 12.4 Arteriocyte Medical Systems
  • 12.5 Athersys Inc.
  • 12.6 Baxter Healthcare Corporation
  • 12.7 Bioheart
  • 12.8 Cambridge Enterprise Ltd
  • 12.9 Celyad
  • 12.10 Celgene Corporation
  • 12.11 Cellerant Therapeutics
  • 12.12 Cellonis Biotechnologies
  • 12.13 CellPraxis
  • 12.14 Chiesi
  • 12.15 Caladrius
  • 12.16 Cryopraxis
  • 12.17 Cytori Therapeutics
  • 12.18 Gamida Cell
  • 12.19 Genexine
  • 12.20 Geron
  • 12.21 Intrexon Corporation
  • 12.22 K-STEMCELL
  • 12.23 Lifecells LLC
  • 12.24 Medipost
  • 12.25 Medistem Panama
  • 12.26 Mesoblast
  • 12.27 Novartis
  • 12.28 Nuo Therapeutics
  • 12.29 Ocata Therapeutics
  • 12.30 OmniCyte Ltd
  • 12.31 OncoMed
  • 12.32 Osiris Therapeutics
  • 12.33 Pharmicell
  • 12.34 Pluristem Therapeutics
  • 12.35 Promethera Biosciences
  • 12.36 ReNeuron
  • 12.37 Stem Cell Sciences (SCS)
  • 12.38 Stem Cells
  • 12.39 Stemedica Cell Technologies
  • 12.40 TCA Cellular Therapy
  • 12.41 TheraVitae
  • 12.42 TiGenix
  • 12.43 Vericel Corporation

List of Figures

  • Figure 1-1: Properties of Stem Cells
  • Figure 1-2: Utility of Stem Cells
  • Figure 1-3: Benefits of Stem Cells
  • Figure 1-4: Limitations of Stem Cells
  • Figure 2-1: Type of Stem Cells on the Basis of Ability to Differentiate
  • Figure 2-2: Type of Stem Cells on the Basis of Origin
  • Figure 2-3: Types of Stem Cells on the Basis of their Source
  • Figure 2-4: Different Sources of Autologous Stem Cell
  • Figure 3-1: Different Stem Cell Transplants
  • Figure 4-1: Source of Hematopoietic Stem Cells
  • Figure 4-2: Mechanism of Stem Cells Blood Related Diseases
  • Figure 4-3: Mechanism of Skin treatment by Stem Cells
  • Figure 4-4: Mechanism of Stem Cell Diabetes Treatment
  • Figure 5-1: Relevant Type of Stem Cells for CVS
  • Figure 5-2: Proposed Mechanism of Stem Cell Activity
  • Figure 6-1: Difference between Autologous & Autogenic HSCTs
  • Figure 6-2: Global Stem Cell Market Opportunity (US$ Billion), 2015-2020
  • Figure 6-3: Global Stem Cell Therapies Clinical Pipeline by Phase (%), 2015
  • Figure 6-4: Global Stem Cell Therapies Clinical Pipeline by Phase (Number), 2015
  • Figure 6-5: No Development Reported Global Stem Cell Therapies Clinical Pipeline by Phase (%), 2015
  • Figure 6-6: No Development Reported Global Stem Cell Therapies Clinical Pipeline by Phase (%), 2015
  • Figure 6-7: Discontinued Global Stem Cell Therapies Clinical Pipeline by Phase (%), 2015
  • Figure 6-8: Discontinued Global Stem Cell Therapies Clinical Pipeline by Phase (Number), 2015
  • Figure 7-1: Global Stem Cell Market Favorable Parameters
  • Figure 7-2: Global Stem Cell Market Commercialization Challenges
  • Figure 12-1: Anterogen - Clinical Pipeline
  • Figure 12-2: Arteriocyte Medical Systems Clinical Pipeline
  • Figure 12-3: Bioheart-Clinical Pipeline
  • Figure 12-4: Celgene-Clinical Pipeline
  • Figure 12-5: Cellerant-Therapeutics Clinical Pipeline
  • Figure 12-6: Caladrius-Clinical Pipeline
  • Figure 12-7: Gamida Cell- Clinical Pipeline
  • Figure 12-8: Genexie-Clinical Pipeline
  • Figure 12-9: Mesoblast Clinical Pipeline
  • Figure 12-10:OncoMed-Clinical Pipeline
  • Figure 12-11: Osiris Therapeutics- Clinical Pipeline
  • Figure 12-12: Pharmicell-Clinical Pipeline
  • Figure 12-13: Promethera- Clinical Pipeline
  • Figure 12-14: ReNeuron-Clinical Pipeline
  • Figure 12-15: Stem Cell-Clinical Pipeline
  • Figure 12-16: Vericel-Clinical Pipeline

List of Tables

  • Table 2-1: Difference between Embryonic, Adult & Induced Stem Cells
  • Table 3-1: Comparison between Different Types of Stem Cell Transplants
  • Table 3-2: Few Autologous Stem Cell Therapies under Development
  • Table 4-1: Different Stem Cells used for Skin Treatment
Back to Top